文献速递临床试验与 GCP

益生菌补充对急性心肌梗死患者院内死亡率的影响:一项开放标签、随机、对照、优效性临床试验的研究方案

Effect of probiotic supplementation on in-hospital mortality in patients with acute myocardial infarction: a study protocol for an open-label, randomized, controlled, superiority clinical trial.
PubMed 文献 · Trials · 2023-06-24

本研究为开放标签、随机、对照、优效性临床试验,计划纳入2594例成人急性心肌梗死患者,随机分为益生菌组(双歧杆菌三联活菌胶囊840 mg,每日两次,最长30天,联合标准治疗)与标准治疗组,主要结局为院内全因死亡率,旨在评估益生菌对院内死亡及主要不良心血管事件的影响。

要点

  • 拟纳入2594例成人急性心肌梗死患者,随机分为益生菌联合标准治疗组与单纯标准治疗组。
  • 益生菌干预为双歧杆菌三联活菌胶囊840 mg每日两次,住院期间最长服用30天。
  • 主要结局为院内全因死亡率,同时评估主要不良心血管事件发生率。

核心结论

  • 该试验旨在确定益生菌能否降低急性心肌梗死患者院内死亡率并改善预后,结果将为益生菌作为急性心肌梗死辅助治疗提供证据。

研究设计与样本

  • 开放标签、随机、对照、优效性临床试验,计划纳入2594例确诊急性心肌梗死的成人患者。
  • 患者随机分为两组:一组接受双歧杆菌三联活菌胶囊(长双歧杆菌、嗜酸乳杆菌和粪肠球菌)840 mg每日两次联合标准治疗,住院期间最长30天;另一组仅接受标准治疗,不服用双歧杆菌三联活菌胶囊。
  • 主要结局为院内全因死亡率。
  • 试验注册于中国临床试验注册中心,注册号ChiCTR2000038797,注册日期2020年10月2日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have demonstrated a correlation between intestinal flora and the severity of myocardial infarction as well as post-myocardial infarction repair. However, few studies have investigated whether probiotics reduce mortality and improve cardiovascular outcomes in patients with acute myocardial infarction. In this study, we will conduct a randomized controlled trial (RCT) to evaluate the effect of probiotics on in-hospital mortality and the incidence of major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). METHODS: This is an open-label, randomized, controlled, superiority clinical trial involving 2594 adult patients who were diagnosed with acute myocardial infarction. Patients will be randomized to (1) receive bifidobacteria triple viable capsule (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) 840 mg, twice a day, plus standard treatment strategy during the hospital stay, for a maximum of 30 days, or (2) receive the standard treatment strategy and will not take the bifidobacterium triple live capsule. The primary outcome was in-hospital all-cause mortality. DISCUSSION: The purpose of this clinical trial is to determine whether probiotics can reduce in-hospital mortality and improve prognosis in patients with AMI, and the results will provide evidence for probiotics as a complementary treatment for AMI. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR2000038797. Registered on 2 October 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen Y, Chen R, Wang X, et al. Effect of probiotic supplementation on in-hospital mortality in patients with acute myocardial infarction: a study protocol for an open-label, randomized, controlled, superiority clinical trial. Trials. 2023. PMID: 37355630. doi:10.1186/s13063-023-07443-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。